A Markov model of glycosylation elucidates isozyme specificity and glycosyltransferase interactions for glycoengineering.

ABSTRACT: Glycosylated biopharmaceuticals are important in the global pharmaceutical market. Despite the importance of their glycan structures, our limited knowledge of the glycosylation machinery still hinders controllability of this critical quality attribute. To facilitate discovery of glycosyltransferase specificity and predict glycoengineering efforts, here we extend the approach to model N-linked protein glycosylation as a Markov process. Our model leverages putative glycosyltransferase (GT) specificity to define the biosynthetic pathways for all measured glycans, and the Markov chain modelling is used to learn glycosyltransferase isoform activities and predict glycosylation following glycosyltransferase knock-in/knockout. We apply our methodology to four different glycoengineered therapeutics

SUBMITTER: Liang C 

PROVIDER: S-EPMC7153765 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature